公开(公告)号：US20220213162A1

公开(公告)日：2022-07-07

申请号：US17578265

申请日：2022-01-18

Applicant: Xencor, Inc.

Inventor： Matthew BERNETT ,  John DESJARLAIS ,  Rajat VARMA ,  Rumana RASHID

IPC: C07K14/55 ,  C07K14/735 ,  C12N15/85

Abstract: The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants.

公开(公告)号：US20240166705A1

公开(公告)日：2024-05-23

申请号：US18503935

申请日：2023-11-07

Applicant: Xencor, Inc.

Inventor： Alex NISTHAL ,  John DESJARLAIS ,  Gregory MOORE ,  Sung-Hyung LEE ,  Matthew Adam DRAGOVICH

IPC: C07K14/54 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K14/54 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/30

Abstract: Provided herein are variant human IL18 proteins including proteins and constructs including such. Various variant IL18 proteins with modifications to reduce heterogeneity and/or reduce affinity/potency and/or improve stability and/or improve production yield are also described. Also provided are IL18-Fc fusion proteins that include an empty-Fc domain and an IL18 protein connected to another Fc domain. Also provided herein are IL18Fc fusion proteins that bind CD3 and a tumor target antigen.

公开(公告)号：US20210101965A1

公开(公告)日：2021-04-08

申请号：US17001604

申请日：2020-08-24

Applicant: ALLERGAN, INC. ,  XENCOR, INC.

Inventor： Peter C. BACIU ,  Yanbin LIANG ,  Jason GUU ,  Matthew BERNETT ,  Umesh MUCHHAL ,  John DESJARLAIS

IPC: C07K16/18 ,  A61K39/00 ,  A61K39/395

Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.